首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2019年 2期 胆汁淤积性肝病诊治的基础与临床 => 专家论坛 =>胆汁淤积性肝病的治疗..
胆汁淤积性肝病的治疗靶点及药物应用前景
New therapeutic targets and drugs for cholestatic liver disease
文章发布日期:2019年01月07日  来源:  作者:郭濛濛,谢雯  点击次数:574次  下载次数:211次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:胆汁淤积性肝病是由胆管的破坏、胆汁酸的积聚和炎症过程的持续导致胆管细胞及肝细胞的损伤而引起。若不及时治疗,胆汁淤积会导致肝纤维化、肝硬化甚至出现终末期肝病。原发性胆汁性胆管炎(PBC)和原发性硬化性胆管炎(PSC)是成人中最常见的2种胆汁淤积性肝病,其病因目前尚不明确。虽然熊去氧胆酸(UDCA)可以较好地改善PBC患者的预后,延长患者肝移植的存活率,但存在部分患者对UDCA治疗无应答的现象。此外,目前尚无有效药物治疗PSC。随着近年来胆汁酸调节分子机制的研究进展及免疫途径的理解加深,涌现了越来越多新的药物。介绍了近年来PBC及PSC新兴治疗靶点及相关药物方面的研究进展。
【Abstract】:Cholestatic liver disease is caused by the damage of bile duct cells and hepatocytes due to bile duct injury, accumulation of bile acids, and persistent inflammation. If it is not treated in time, cholestasis can lead to liver fibrosis, liver cirrhosis, and even end-stage liver disease. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the two most common cholestatic liver diseases in adults, with unknown causes. Although ursodeoxycholic acid (UDCA) can improve the prognosis of PBC patients and prolong survival time after liver transplantation, some patients have no response to UDCA. In addition, there are still no effective pharmacotherapies for PSC. With the research advances in molecular mechanism of bile acid regulation and a deeper understanding of immune pathways in recent years, several new drugs have emerged. This article introduces the new therapeutic targets and drugs for PBC and PSC.
【关键字】:胆汁淤积; 肝硬化, 胆汁性; 胆管炎, 硬化性; 治疗学
【Key words】:cholestasis; liver cirrhosis, biliary; cholangitis, sclerosing; therapeutics
【引证本文】:GUO MM, XIE W. New therapeutic targets and drugs for cholestatic liver disease[J]. J Clin Hepatol, 2019, 35(2): 262-265. (in Chinese)
郭濛濛, 谢雯. 胆汁淤积性肝病的治疗靶点及药物应用前景[J]. 临床肝胆病杂志, 2019, 35(2): 262-265.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号